Malignant Hyperthermia

Malignant hyperthermia (MH) is a rare, inherited condition that causes a severe reaction to certain anesthesia medications used during surgery. It leads to a rapid increase in body temperature, muscle rigidity, and a fast heart rate. If not treated quickly, it can be life-threatening, making early recognition and immediate treatment critical.

What is Malignant Hyperthermia?

Malignant hyperthermia (MH) is a serious, inherited condition where certain anesthesia drugs trigger a dangerous reaction in susceptible individuals. This reaction causes muscles to contract uncontrollably, leading to a rapid rise in body temperature, increased heart rate, and other severe symptoms. It is a medical emergency that requires immediate treatment.

Malignant hyperthermia is a genetic disorder that affects how muscle cells respond to specific medications. When a person with MH is exposed to certain inhaled anesthetics or a muscle relaxant called succinylcholine, their muscle cells release too much calcium. This uncontrolled calcium release causes continuous muscle contraction. These sustained muscle contractions generate a lot of heat, leading to a dangerously high body temperature (hyperthermia). The body's metabolism also speeds up, producing excess carbon dioxide and lactic acid. This can lead to a condition called acidosis, where the body's fluids become too acidic. MH is considered rare, affecting about 1 in 10,000 to 1 in 50,000 people who receive general anesthesia. Despite its rarity, it is crucial to identify and treat MH quickly because it can lead to serious complications, including organ damage or death, if left untreated.

Symptoms

Symptoms of malignant hyperthermia usually appear during or shortly after surgery when a person receives triggering anesthesia medications. Key signs include a sudden, unexplained high fever, a very fast heart rate, rapid breathing, and severe muscle stiffness or rigidity. Early recognition of these symptoms is vital for prompt treatment.

The most noticeable symptom of malignant hyperthermia is a sudden and rapid increase in body temperature, which can rise several degrees in a short amount of time. This high fever is often accompanied by a fast and irregular heartbeat (tachycardia or arrhythmia), as the heart works harder to pump blood. Muscles throughout the body may become stiff and rigid, especially in the jaw, neck, and chest. This muscle rigidity is a direct result of the uncontrolled calcium release within muscle cells. People may also experience rapid and deep breathing, as the body tries to get rid of excess carbon dioxide produced by the overactive muscles. Other symptoms can include dark brown urine, which indicates muscle breakdown (rhabdomyolysis) and the release of muscle proteins into the bloodstream. Blood tests may show high levels of potassium and carbon dioxide, and low oxygen levels. These symptoms collectively signal a life-threatening crisis that requires immediate medical intervention.

Causes & risk factors

Malignant hyperthermia is caused by a genetic change (mutation) in specific genes that control calcium release in muscle cells. The primary risk factor is having this genetic mutation, which is usually inherited. Exposure to certain inhaled anesthesia gases or the muscle relaxant succinylcholine triggers the reaction in susceptible individuals.

The underlying cause of malignant hyperthermia is a genetic mutation, most commonly in the RYR1 gene. This gene provides instructions for making a protein called the ryanodine receptor, which is crucial for regulating calcium release from storage sacs within muscle cells. In people with MH, this receptor is overactive, leading to excessive calcium release when exposed to triggers. MH is inherited in an autosomal dominant pattern. This means that if one parent has the genetic mutation, there is a 50% chance that each child will also inherit the mutation and be susceptible to MH. A family history of MH or unexplained severe reactions to anesthesia is a significant risk factor. The specific triggers for an MH crisis are certain volatile anesthetic gases, such as halothane, isoflurane, sevoflurane, and desflurane, and the muscle relaxant succinylcholine. These drugs are commonly used during general anesthesia. People with the genetic predisposition will only experience an MH episode if they are exposed to one of these triggering agents.

How it's diagnosed

Malignant hyperthermia is often diagnosed during surgery based on the sudden appearance of symptoms after exposure to triggering anesthesia. After an episode, a muscle biopsy, specifically the caffeine-halothane contracture test, is the most reliable diagnostic test. Genetic testing can also identify specific gene mutations associated with MH.

During an anesthetic procedure, doctors diagnose malignant hyperthermia based on the rapid development of characteristic symptoms. These include a sudden increase in carbon dioxide levels, a fast heart rate, muscle rigidity, and a rapid rise in body temperature. The medical team will immediately stop the triggering anesthetic and begin emergency treatment. To confirm a diagnosis of MH susceptibility, especially for family members at risk, a muscle biopsy is often performed. This involves taking a small sample of muscle tissue, usually from the thigh. The muscle tissue is then exposed to caffeine and halothane in a lab setting (caffeine-halothane contracture test). If the muscle contracts excessively, it indicates susceptibility to MH. Genetic testing can also be used to identify specific mutations in genes like RYR1 that are known to cause MH. While genetic testing is less invasive than a muscle biopsy, it may not identify all MH-causing mutations, as some cases have no known genetic cause. Both tests help determine a person's risk and guide future anesthesia planning.

Treatment options

The primary treatment for an acute malignant hyperthermia crisis is an emergency medication called dantrolene. This drug helps relax muscles and reduce heat production. During an MH episode, doctors also immediately stop the triggering anesthetic, cool the body, and provide supportive care to manage complications like acidosis and organ damage.

When an MH crisis occurs, the first step is to immediately stop administering the triggering anesthetic agents and switch to non-triggering ones. The operating room team will then administer dantrolene intravenously. Dantrolene works by interfering with calcium release from muscle cells, which helps to relax the muscles and reduce the excessive heat production. Alongside dantrolene, supportive measures are critical. These include actively cooling the person's body to lower their dangerously high temperature, often using ice packs, cooling blankets, and cold intravenous fluids. Doctors will also work to correct metabolic imbalances, such as acidosis, by administering bicarbonate, and manage any heart rhythm problems. Monitoring vital signs, urine output, and blood tests is continuous to assess for complications like kidney failure or heart issues. For individuals known to be susceptible to MH, prevention is key. This involves creating an anesthesia plan that strictly avoids all known triggering agents, using alternative medications, and ensuring dantrolene is readily available.

Recovery & outlook

With prompt recognition and immediate treatment, most people recover well from a malignant hyperthermia crisis. Recovery involves close monitoring for potential complications, such as kidney damage or muscle weakness. After recovery, individuals must take precautions to avoid future episodes, including informing all healthcare providers about their MH susceptibility.

The outlook for someone experiencing a malignant hyperthermia crisis has significantly improved since the introduction of dantrolene. If treatment is started quickly, the survival rate is very high. However, delays in diagnosis or treatment can lead to serious complications, including kidney failure dueain injury, heart problems, or even death. After an MH episode, a person will be closely monitored in an intensive care unit for several days. This is to ensure that their body temperature stabilizes, muscle breakdown products are cleared, and organ function returns to normal. Some people may experience temporary muscle weakness or soreness during recovery. Long-term management focuses on preventing future episodes. Individuals who have experienced MH or are known to be susceptible should wear a medical alert bracelet or carry identification stating their condition. It is crucial to inform all doctors, dentists, and other healthcare providers about MH susceptibility before any procedure requiring anesthesia, so they can plan to use safe, non-triggering medications.

When to see a doctor

If you have a family history of malignant hyperthermia or have experienced any unusual or severe reactions to anesthesia in the past, it is crucial to inform your doctor before any planned surgery or procedure. If symptoms of MH, such as a sudden high fever or muscle rigidity, appear during or after anesthesia, seek emergency medical care immediately.

It is extremely important to discuss your family medical history with your doctor, especially if any family members have had a diagnosis of malignant hyperthermia or experienced unexplained complications during surgery. This information allows your healthcare team to take necessary precautions and plan for safe anesthesia. Before any surgery or procedure requiring anesthesia, make sure to tell your anesthesiologist and surgeon if you or a blood relative has ever had a reaction to anesthesia. This includes any unexplained fevers, muscle stiffness, or other severe symptoms. This allows them to use non-triggering anesthetic agents and have dantrolene readily available. If you are undergoing surgery and you or your family members notice any signs of malignant hyperthermia, such as a sudden high fever, rapid heart rate, or muscle rigidity, alert the medical staff immediately. These symptoms constitute a medical emergency, and prompt action can be life-saving. Do not delay in seeking help.

Frequently asked questions

Is malignant hyperthermia always inherited?

Yes, malignant hyperthermia is almost always an inherited condition. It is caused by a genetic mutation, most commonly in the RYR1 gene, which is passed down through families. While rare, some cases may arise from new mutations, but the genetic link is fundamental to the condition.

Can malignant hyperthermia happen without surgery?

Malignant hyperthermia typically only occurs when a susceptible person is exposed to specific triggering anesthetic gases or the muscle relaxant succinylcholine, which are used during surgery. It does not usually happen spontaneously outside of this exposure, though some rare, exertional heat stroke cases can mimic MH symptoms.

What if I need surgery and have malignant hyperthermia?

If you have malignant hyperthermia, you can still have surgery. Your medical team will create a special anesthesia plan that avoids all known triggering agents. They will use alternative, safe medications and ensure that dantrolene, the emergency treatment, is immediately available. Always inform your doctors about your condition.

How common is malignant hyperthermia?

Malignant hyperthermia is considered rare. It is estimated to affect about 1 in 10,000 to 1 in 50,000 people who receive general anesthesia. While uncommon, its potential severity makes awareness and preparedness crucial for healthcare providers and susceptible individuals.

Are there other conditions similar to malignant hyperthermia?

Yes, some other conditions can present with similar symptoms, such as heat stroke, sepsis (a severe infection), or thyroid storm. However, malignant hyperthermia is distinct because it is specifically triggered by certain anesthesia drugs in genetically susceptible individuals. Doctors use specific tests to differentiate these conditions.

Can I be tested for malignant hyperthermia if no one in my family has had it?

Testing for malignant hyperthermia is usually recommended if you have a family history of the condition or have had an unexplained severe reaction to anesthesia. If there's no known family history or prior reaction, routine testing is not typically done due to the invasiveness of the muscle biopsy and the rarity of the condition.

Sources

• MedlinePlus — Malignant Hyperthermia
• Mayo Clinic — Malignant Hyperthermia
• Cochrane Library — Malignant Hyperthermia